Hearing ‐ return to normal *Ventilation tubes versus laser myringotomy (6 to 12 months ‐ medium‐term) Adjusted for non‐independence of within‐individual measurements Assumed ICC of 0.5 № of participants: 132 (2 RCTs) · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids showed no clear difference in hearing ‐ return to normal hearing compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.14 [0.97, 1.33]
Studies not reported
Moderate
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids may leads to lower presence/persistence of OME compared with placebo (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether oral steroids changes adverse event: systemic corticosteroid side effects compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Hearing · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids showed no clear difference in presence/persistence of OME (3 to 9 months ‐ medium‐term) № of… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.02 [0.89, 1.17]
Studies not reported
Low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in complete remission Time frame: 4 weeks compared with oral steroids alone (moderate certainty).
2 findings from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in complete or partial remission Time frame: 24 weeks to end of treatment compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Relapse · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in relapse Time frame: 24 weeks compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: death · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
1 finding from 1 review
Acute kidney injury · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).
1 finding from 1 review
Adverse events: new‐onset glucose intolerance · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: new‐onset glucose intolerance compared with oral steroids alone (low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in complete remission Time frame: 2 to 6 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review